NO20011891L - Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjon - Google Patents
Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjonInfo
- Publication number
- NO20011891L NO20011891L NO20011891A NO20011891A NO20011891L NO 20011891 L NO20011891 L NO 20011891L NO 20011891 A NO20011891 A NO 20011891A NO 20011891 A NO20011891 A NO 20011891A NO 20011891 L NO20011891 L NO 20011891L
- Authority
- NO
- Norway
- Prior art keywords
- beta
- inhibitors
- screening
- amyloid
- radioligands
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 238000012216 screening Methods 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 239000002287 radioligand Substances 0.000 title 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10814798P | 1998-11-12 | 1998-11-12 | |
| US13128499P | 1999-04-27 | 1999-04-27 | |
| PCT/US1999/026715 WO2000028331A1 (fr) | 1998-11-12 | 1999-11-12 | Utilisation de radioligands pour detecter des inhibiteurs de la production de peptides beta-amyloides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20011891D0 NO20011891D0 (no) | 2001-04-17 |
| NO20011891L true NO20011891L (no) | 2001-07-02 |
Family
ID=26805566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20011891A NO20011891L (no) | 1998-11-12 | 2001-04-17 | Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjon |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6331408B1 (fr) |
| EP (1) | EP1129355B1 (fr) |
| AT (1) | ATE300052T1 (fr) |
| AU (1) | AU1618000A (fr) |
| CA (1) | CA2346099A1 (fr) |
| DE (1) | DE69926254D1 (fr) |
| NO (1) | NO20011891L (fr) |
| WO (1) | WO2000028331A1 (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP990246A2 (en) | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
| NZ525513A (en) | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
| US6737038B1 (en) * | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| AU1618000A (en) * | 1998-11-12 | 2000-05-29 | Du Pont Pharmaceuticals Company | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
| WO2000038618A2 (fr) | 1998-12-24 | 2000-07-06 | Du Pont Pharmaceuticals Company | BENZODIAZEPINES SUCCINOYLAMINO UTILISEES COMME INHIBITEURS DE LA PRODUCTION DE PROTEINE A$g(b) |
| US6518011B1 (en) * | 1999-01-13 | 2003-02-11 | Bristol-Myers Squibb Company | Method for screening compounds to identify beta-amyloid production modulators |
| DE19909357A1 (de) * | 1999-03-03 | 2000-09-07 | Gerd Multhaup | Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt |
| CA2395862A1 (fr) | 2000-02-17 | 2001-08-23 | Hong Liu | Carbocycles et heterocycles succinoylamino utilises en tant qu'inhibiteurs de la production de la proteine a.beta. |
| EP1268434A1 (fr) | 2000-04-03 | 2003-01-02 | Bristol-Myers Squibb Pharma Company | Lactames cycliques utiles en tant qu'inhibiteurs de la production de proteine a-beta |
| CN1436175A (zh) | 2000-04-03 | 2003-08-13 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为Aβ-蛋白生产抑制剂的环状内酰胺 |
| US6878363B2 (en) * | 2000-05-17 | 2005-04-12 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| CN1386118A (zh) | 2000-06-01 | 2002-12-18 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物 |
| DK1379634T3 (en) * | 2001-04-20 | 2018-03-19 | The Univ Of Georgia Research Foundation Inc | ACTIVE LOCATION INACTIVATORS |
| US20090062256A1 (en) * | 2001-06-01 | 2009-03-05 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
| CH698246B1 (de) * | 2001-12-20 | 2009-06-30 | Hoffmann La Roche | Test zur Identifizierung von Inhibitoren von Beta-Sekretasen. |
| US7906625B2 (en) | 2005-01-24 | 2011-03-15 | Amgen Inc. | Humanized anti-amyloid antibody |
| EP2235058A2 (fr) | 2007-12-21 | 2010-10-06 | Amgen, Inc | Anticorps anti-amyloïde et utilisations de ceux-ci |
| TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯二氮呯酮化合物 |
| US9242940B2 (en) | 2012-09-21 | 2016-01-26 | Bristol-Myers Squibb Company | N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
| WO2014047370A1 (fr) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Composés fluoroalkyl benzodiazépinones |
| CN104797569A (zh) | 2012-09-21 | 2015-07-22 | 百时美施贵宝公司 | 取代的1,5-苯并二氮杂*酮化合物 |
| TWI614238B (zh) * | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥 |
| CN104797584A (zh) | 2012-09-21 | 2015-07-22 | 百时美施贵宝公司 | 作为notch抑制剂的三环杂环化合物 |
| JP2015531792A (ja) | 2012-09-21 | 2015-11-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 1,4−ベンゾジアゼピノン化合物のプロドラッグ |
| CN105308030A (zh) | 2012-09-21 | 2016-02-03 | 百时美施贵宝公司 | 烷基、氟烷基-1,4-苯并二氮杂*酮化合物 |
| WO2014047392A1 (fr) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Composés fluoroalkyl-1,4-benzodiazépinones |
| EP2897942B1 (fr) | 2012-09-21 | 2016-08-31 | Bristol-Myers Squibb Company | Composés de fluoralkyl- et de fluorocycloalkyl-1,4-benzodiazépinone utilisables en tant qu'inhibiteurs du récepteur notch |
| EP2981267A1 (fr) | 2013-04-04 | 2016-02-10 | Bristol-Myers Squibb Company | Traitement combiné pour le traitement de maladies prolifératives |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZW23187A1 (en) * | 1986-12-15 | 1988-06-29 | Hoffmann La Roche | Phosphinic acid derivatives |
| US5252463A (en) * | 1990-06-22 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Clipsin, a chymotrypsin-like protease and method of using same |
| GB9022117D0 (en) * | 1990-10-11 | 1990-11-21 | Beecham Group Plc | Novel compounds |
| US5434050A (en) * | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
| US5538845A (en) * | 1992-02-05 | 1996-07-23 | Athena Neurosciences, Inc. | Beta-amyloid peptide production inhibitors and methods for their identification |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5594006A (en) * | 1993-03-18 | 1997-01-14 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives as matrix metalloproteinases inhibitors |
| AU6909194A (en) * | 1993-05-14 | 1994-12-12 | Board Of Regents, The University Of Texas System | Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole |
| NZ264143A (en) * | 1993-08-09 | 1996-11-26 | Lilly Co Eli | Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production |
| US5514716A (en) * | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
| US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
| JPH11507538A (ja) * | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| US5703129A (en) * | 1996-09-30 | 1997-12-30 | Bristol-Myers Squibb Company | 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production |
| WO1998015828A1 (fr) * | 1996-10-07 | 1998-04-16 | Scios Inc. | METHODE D'IDENTIFICATION DES INHIBITEURS DIRECTS DE L'ENZYME η-SECRETASE PRODUISANT LE β-AMYLOIDE |
| US5734054A (en) * | 1996-11-05 | 1998-03-31 | Pharmacopeia, Inc. | Hydroxy-amino acid amides |
| AU1618000A (en) * | 1998-11-12 | 2000-05-29 | Du Pont Pharmaceuticals Company | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
-
1999
- 1999-11-12 AU AU16180/00A patent/AU1618000A/en not_active Abandoned
- 1999-11-12 EP EP99958905A patent/EP1129355B1/fr not_active Expired - Lifetime
- 1999-11-12 US US09/438,901 patent/US6331408B1/en not_active Expired - Lifetime
- 1999-11-12 CA CA002346099A patent/CA2346099A1/fr not_active Abandoned
- 1999-11-12 WO PCT/US1999/026715 patent/WO2000028331A1/fr not_active Ceased
- 1999-11-12 DE DE69926254T patent/DE69926254D1/de not_active Expired - Lifetime
- 1999-11-12 AT AT99958905T patent/ATE300052T1/de not_active IP Right Cessation
-
2001
- 2001-04-17 NO NO20011891A patent/NO20011891L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US6331408B1 (en) | 2001-12-18 |
| CA2346099A1 (fr) | 2000-05-18 |
| NO20011891D0 (no) | 2001-04-17 |
| EP1129355A1 (fr) | 2001-09-05 |
| EP1129355B1 (fr) | 2005-07-20 |
| WO2000028331A1 (fr) | 2000-05-18 |
| AU1618000A (en) | 2000-05-29 |
| DE69926254D1 (de) | 2005-08-25 |
| ATE300052T1 (de) | 2005-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20011891D0 (no) | Anvendelse av radioligander for screening av inhibitorer av amyloid-<beta>-peptid produksjon | |
| DE69429527D1 (de) | Inhibitoren von beta-amyloid-protein-herstellung | |
| DE69432629D1 (de) | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung | |
| WO2001087354A3 (fr) | Utilisation de radioligands a petites molecules en vue de rechercher des inhibiteurs de production d'amyloide-beta et destine a l'imagerie diagnostique | |
| WO2003042654A3 (fr) | Methodes de criblage a haut debit a parametres multiples | |
| WO2003104418A3 (fr) | Polypeptides reconstitues | |
| GB0117326D0 (en) | Napthoquinone-type inhibitors of protein aggregation | |
| WO2005018424A3 (fr) | Anticorps specifiques de la proteine amyloide fibrillaire et procedure permettant de detecter des depots de proteines amyloides fibrillaires | |
| MY131442A (en) | Excitatory amino acid receptor antagonists | |
| MXPA05003621A (es) | Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos. | |
| TW200502221A (en) | Novel lactams and uses thereof | |
| EA200400699A1 (ru) | 3,4-дизамещенные, 3,5-дизамещенные и 3,4,5-замещенные пиперидины и пиперазины | |
| NO20063196L (no) | Nye fusjonerte pyrrolokarbazoler | |
| NO20063193L (no) | Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav | |
| ATE522230T1 (de) | Biphenyle als bilderzeugungsmittel bei der alzheimerschen krankheit | |
| DE69808475D1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| IL169889A0 (en) | Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| MY120085A (en) | Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines. | |
| WO2004005882A3 (fr) | Methodes de criblage a haut rendement multi-parametres (mphts) | |
| TW200504036A (en) | Novel lactams and uses thereof | |
| BR0314541A (pt) | Tratamento de demência e doença de parkinson | |
| WO2001049871A3 (fr) | Methode de recherche d'un inhibiteur de protease | |
| WO2004047854A3 (fr) | Procedes de traitement de la maladie d'alzheimer et compositions afferentes | |
| WO1999006838A3 (fr) | Nouveau procede pour detecter des agregats de proteines ou des fibrilles du type amyloide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |